Focused On-demand Library for Endosomal/lysosomal proton channel TMEM175

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Transmembrane protein 175

Alternative UPACC:

Q9BSA9; D3DVN4; Q8ND13


The Endosomal/lysosomal proton channel TMEM175, also known as Transmembrane protein 175, plays a pivotal role in maintaining pH homeostasis within endosomes and lysosomes. This protein functions as a proton-activated proton channel, facilitating proton efflux to regulate the steady-state pH. Additionally, TMEM175 may operate as a potassium channel, influencing potassium conductance. Its involvement in autophagosome-lysosome fusion underscores its importance in cellular processes.

Therapeutic significance:

TMEM175's dysfunction is linked to Parkinson disease, a neurodegenerative disorder characterized by motor and cognitive impairments. Variants affecting TMEM175 contribute to unstable lysosomal pH, impacting autophagosome clearance and mitochondrial respiration. Understanding TMEM175's role could pave the way for novel therapeutic strategies targeting lysosomal dysfunction in Parkinson's disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.